Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05594745 · ClinicalTrials.gov registry record · Phase 4
Treatment Regimens in Meibomian Gland Dysfunction
A Phase 4 study, sponsored by Tauber Eye Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT05594745 is a Phase 4 study that has completed, run by Tauber Eye Center. The registered enrollment target is 60 participants.
The verdict
NCT05594745, a Phase 4 study, has completed, sponsored by Tauber Eye Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study seeks to explore the relevance of inflammation in dry eye patients with MGD and compare the efficacy of LipiFlow treatment followed by lid hygiene and lubricant treatment with Systane Ultra or LipiFlow treatment followed by lid hygiene and lifitegrast treatment in patients with meibomian gland dysfunction.
Interventions
- DRUG Lifitegrast Ophthalmic
- DRUG Systane Free
- DEVICE Lipiflow
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-03-02 |
| Est. Completion | 2023-01-21 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05594745
The ClinicalTrials.gov registry entry for NCT05594745 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tauber Eye Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lifitegrast Ophthalmic is the first listed.
NCT05594745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05594745 about?
NCT05594745 is a clinical study titled "Treatment Regimens in Meibomian Gland Dysfunction". This study seeks to explore the relevance of inflammation in dry eye patients with MGD and compare the efficacy of LipiFlow treatment followed by lid hygiene and lubricant treatment with Systane Ultra or LipiFlow treatment followed by lid hygiene and lifitegrast treatment in patients with meibomian ...
What is the current status of trial NCT05594745?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2021-03-02. Estimated completion is 2023-01-21.
What interventions are being tested in trial NCT05594745?
The interventions under investigation include: Lifitegrast Ophthalmic (DRUG), Systane Free (DRUG), Lipiflow (DEVICE).
Who is sponsoring clinical trial NCT05594745?
This trial is sponsored by Tauber Eye Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.